GW researchers review studies on treatments for prurigo nodularis

A team from the George Washington University reviewed 35 studies on treatments for prurigo nodularis

Prurigo nodularis is a disabling chronic skin condition characterized by severely itchy, crusty, firm papules and nodules that often occur on the arms and legs, but can appear diffusely on the body. The pathogenesis of prurigo nodularis is poorly understood, as this condition has been associated with a broad array of primary skin and underlying medical diseases affecting the liver, kidneys, and blood.

Adam Friedman, MD, professor of dermatology at GW School of Medicine and Health Sciences

Regardless of the cause of these lesions, impact on quality of life for these patients can be tremendous, as the itch associated with the lesions can both aggravate and initiate stress, further perpetuating the itch-scratch cycle and induce further lesion formation. Many of the treatment options, including topical agents, phototherapy, and systemic immunomodulatory drugs, show limited promise due to side effects and low efficacy.

A team at the George Washington University (GW) has conducted a systematic review of clinical studies investigating prurigo nodularis treatment published between 1990 and the present that include at least five subjects.

Currently, there is a lack of targeted pharmacologic therapy for prurigo nodularis and all current treatment approaches utilized show variable success. We wanted to provide a summary of evidence-based treatments to highlights promising directions and also underscore areas that require improvement."

Adam Friedman, MD, professor of dermatology at the GW School of Medicine and Health Sciences and senior author on the study

Friedman and his team looked at 35 studies with differences in factors such as the number of subjects and the delivery of the treatment. They gave a score to each study, ranking its efficacy and consistency against prurigo nodularis.

In the review, the team found the most promise in emerging treatments, such as neurokinin-1 receptor antagonists, part of a drug class used to treat nausea and vomiting associated with chemotherapy. The receptor is a target of substance P, a mediator of itch and a probable pathogenic agent of prurigo nodularis.

By identifying which current and future therapies are effective for prurigo nodularis, we can gain a better understanding of the biological underpinnings of this disease, and patients will ultimately benefit from better treatment options. Our summary not only provides guidance for practitioners with regards to the broad array of off-label therapies in our armament, but also to researchers in identifying the gaps in treatment development."

Adam Friedman

The team suggests that higher-powered studies and additional randomized controlled trials are needed to better evaluate treatment options for prurigo nodularis.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative blood test boosts accuracy of lung cancer screening